Logo image of EVGN

EVOGENE LTD (EVGN) Stock Fundamental Analysis

NASDAQ:EVGN - Nasdaq - IL0011050551 - Common Stock - Currency: USD

1.57  +0.03 (+1.95%)

After market: 1.57 0 (0%)

Fundamental Rating

2

Taking everything into account, EVGN scores 2 out of 10 in our fundamental rating. EVGN was compared to 572 industry peers in the Biotechnology industry. Both the profitability and financial health of EVGN have multiple concerns. EVGN is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

EVGN had negative earnings in the past year.
EVGN had a negative operating cash flow in the past year.
EVGN had negative earnings in each of the past 5 years.
EVGN had a negative operating cash flow in each of the past 5 years.
EVGN Yearly Net Income VS EBIT VS OCF VS FCFEVGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

EVGN has a Return On Assets (-58.62%) which is in line with its industry peers.
Industry RankSector Rank
ROA -58.62%
ROE N/A
ROIC N/A
ROA(3y)-43.55%
ROA(5y)-37.7%
ROE(3y)-115.12%
ROE(5y)-86.46%
ROIC(3y)N/A
ROIC(5y)N/A
EVGN Yearly ROA, ROE, ROICEVGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

EVGN has a Gross Margin of 68.90%. This is amongst the best in the industry. EVGN outperforms 82.65% of its industry peers.
The Profit Margin and Operating Margin are not available for EVGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.9%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EVGN Yearly Profit, Operating, Gross MarginsEVGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K

More info and screens

2

2. Health

2.1 Basic Checks

EVGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EVGN has less shares outstanding
EVGN has less shares outstanding than it did 5 years ago.
EVGN has a worse debt/assets ratio than last year.
EVGN Yearly Shares OutstandingEVGN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
EVGN Yearly Total Debt VS Total AssetsEVGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

EVGN has an Altman-Z score of -11.26. This is a bad value and indicates that EVGN is not financially healthy and even has some risk of bankruptcy.
EVGN has a Altman-Z score of -11.26. This is in the lower half of the industry: EVGN underperforms 77.17% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -11.26
ROIC/WACCN/A
WACC5.92%
EVGN Yearly LT Debt VS Equity VS FCFEVGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M 80M 100M

2.3 Liquidity

EVGN has a Current Ratio of 1.09. This is a normal value and indicates that EVGN is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of EVGN (1.09) is worse than 87.08% of its industry peers.
EVGN has a Quick Ratio of 1.03. This is a normal value and indicates that EVGN is financially healthy and should not expect problems in meeting its short term obligations.
EVGN has a worse Quick ratio (1.03) than 86.73% of its industry peers.
Industry RankSector Rank
Current Ratio 1.09
Quick Ratio 1.03
EVGN Yearly Current Assets VS Current LiabilitesEVGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

7

3. Growth

3.1 Past

EVGN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.89%.
The Revenue has grown by 30.80% in the past year. This is a very strong growth!
The Revenue has been growing by 26.37% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)4.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-63.75%
Revenue 1Y (TTM)30.8%
Revenue growth 3Y75.69%
Revenue growth 5Y26.37%
Sales Q2Q%-52.32%

3.2 Future

EVGN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.39% yearly.
Based on estimates for the next years, EVGN will show a very strong growth in Revenue. The Revenue will grow by 67.38% on average per year.
EPS Next Y20.81%
EPS Next 2Y18.38%
EPS Next 3Y16.39%
EPS Next 5YN/A
Revenue Next Year89.65%
Revenue Next 2Y62.19%
Revenue Next 3Y67.38%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
EVGN Yearly Revenue VS EstimatesEVGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M
EVGN Yearly EPS VS EstimatesEVGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

EVGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EVGN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EVGN Price Earnings VS Forward Price EarningsEVGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EVGN Per share dataEVGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as EVGN's earnings are expected to grow with 16.39% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.38%
EPS Next 3Y16.39%

More info and screens

0

5. Dividend

5.1 Amount

EVGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVOGENE LTD

NASDAQ:EVGN (1/29/2025, 8:21:43 PM)

After market: 1.57 0 (0%)

1.57

+0.03 (+1.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-21 2024-11-21/bmo
Earnings (Next)N/A N/A
Inst Owners7.96%
Inst Owner Change-0.3%
Ins Owners1.66%
Ins Owner ChangeN/A
Market Cap8.43M
Analysts82.5
Price Target8.29 (428.03%)
Short Float %0.4%
Short Ratio0.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.15%
Min EPS beat(2)-27.16%
Max EPS beat(2)16.86%
EPS beat(4)3
Avg EPS beat(4)4.03%
Min EPS beat(4)-27.16%
Max EPS beat(4)17.44%
EPS beat(8)7
Avg EPS beat(8)18.07%
EPS beat(12)9
Avg EPS beat(12)12.8%
EPS beat(16)11
Avg EPS beat(16)7.85%
Revenue beat(2)1
Avg Revenue beat(2)-13.1%
Min Revenue beat(2)-38.22%
Max Revenue beat(2)12.01%
Revenue beat(4)3
Avg Revenue beat(4)1.12%
Min Revenue beat(4)-38.22%
Max Revenue beat(4)17.37%
Revenue beat(8)5
Avg Revenue beat(8)26.79%
Revenue beat(12)8
Avg Revenue beat(12)67.45%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-39.81%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-543.48%
EPS NY rev (1m)0%
EPS NY rev (3m)-12.89%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)20.85%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-30.3%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.13
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.47
EYN/A
EPS(NY)-3.17
Fwd EYN/A
FCF(TTM)-3.87
FCFYN/A
OCF(TTM)-3.8
OCFYN/A
SpS1.39
BVpS-0.81
TBVpS-3.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -58.62%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.9%
FCFM N/A
ROA(3y)-43.55%
ROA(5y)-37.7%
ROE(3y)-115.12%
ROE(5y)-86.46%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.15%
Cap/Sales 5.22%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.09
Quick Ratio 1.03
Altman-Z -11.26
F-Score3
WACC5.92%
ROIC/WACCN/A
Cap/Depr(3y)37.84%
Cap/Depr(5y)34.18%
Cap/Sales(3y)58.32%
Cap/Sales(5y)72.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-63.75%
EPS Next Y20.81%
EPS Next 2Y18.38%
EPS Next 3Y16.39%
EPS Next 5YN/A
Revenue 1Y (TTM)30.8%
Revenue growth 3Y75.69%
Revenue growth 5Y26.37%
Sales Q2Q%-52.32%
Revenue Next Year89.65%
Revenue Next 2Y62.19%
Revenue Next 3Y67.38%
Revenue Next 5YN/A
EBIT growth 1Y5.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year36.69%
EBIT Next 3Y15.29%
EBIT Next 5YN/A
FCF growth 1Y32.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.81%
OCF growth 3YN/A
OCF growth 5YN/A